Liver-specific expression of the agouti gene in transgenic mice promotes liver carcinogenesis in the absence of obesity and diabetes
详细信息 查看全文
- 作者：Alexander I Kuklin (1) (3)
Randall L Mynatt (1) (4)
Mitchell L Klebig (1) (5)
Laura L Kiefer (2) (6)
William O Wilkison (2) (7)
Richard P Woychik (1) (8)
Edward J Michaud (1) - 刊名：Molecular Cancer
- 出版年：2004
- 出版时间：December 2004
- 年：2004
- 卷：3
- 期：1
- 全文大小：757KB
- 参考文献：1. Silvers WK: The agouti and extension series of alleles, umbrous, and sable. / In The Coat Colors of Mice: A Model for Mammalian Gene Action and Interaction New York: Springer-Verlag 1979, 6-4.
2. Bultman SJ, Michaud EJ, Woychik RP: Molecular characterization of the mouse agouti locus. / Cell 1992, 71:1195-204. CrossRef
3. Miller MW, Duhl DMJ, Vrieling H, Cordes SP, Ollmann MM, Winkes BM, Barsh GS: Cloning of the mouse agouti gene predicts a secreted protein ubiquitously expressed in mice carrying the lethal yellow mutation. / Genes Dev 1993, 7:454-67. CrossRef
4. Matsunaga N, Virador V, Santis C, Vieira WD, Furumura M, Matsunaga J, Kobayashi N, Hearing VJ: In situ localization of agouti signal protein in murine skin using immunohistochemistry with an ASP-specific antibody. / Biochem Biophys Res Commun 2000, 270:176-82. CrossRef
5. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD: Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. / Nature 1994, 371:799-02. CrossRef
6. Blanchard SG, Harris CO, Ittoop OR, Nichols JS, Parks DJ, Truesdale AT, Wilkison WO: Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line. / Biochemistry 1995, 34:10406-0411. CrossRef
7. Siegrist W, Drozdz R, Cotti R, Willard DH, Wilkison WO, Eberle AN: Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. / J Recept Signal Transduct Res 1997, 17:75-8. CrossRef
8. Ollmann MM, Lamoreux ML, Wilson BD, Barsh GS: Interaction of Agouti protein with the melanocortin 1 receptor
9. Eberle AN, Bodi J, Orosz G, Suli-Vargha H, Jaggin V, Zumsteg U: Antagonist and agonist activities of the mouse agouti protein fragment (91-31) at the melanocortin-1 receptor. / J Recept Signal Transduct Res 2001, 21:25-5. CrossRef
10. Abdel-Malek ZA, Scott MC, Furumura M, Lamoreux ML, Ollmann M, Barsh GS, Hearing VJ: The melanocortin 1 receptor is the principle mediator of the effects of agouti signaling protein on mammalian melanocytes. / J Cell Sci 2001, 114:1019-024.
11. Hustad CM, Perry WL, Siracusa LD, Rasberry C, Cobb L, Cattanach BM, Kovatch R, Copeland NG, Jenkins NA: Molecular genetic characterization of six recessive viable alleles of the mouse agouti locus. / Genetics 1995, 140:255-65.
12. Miltenberger RJ, Wakamatsu K, Ito S, Woychik RP, Russell LB, Michaud EJ: Molecular and phenotypic analysis of 25 recessive, homozygous-viable alleles at the mouse agouti locus. / Genetics 2002, 160:659-74.
13. Wolff GL, Roberts DW, Galbraith DB: Prenatal determination of obesity, tumor susceptibility, and coat color pattern in viable yellow (
14. Wolff GL: Body weight and cancer. / Am J Clin Nutr 1987, 45:168-80.
15. Jackson IJ: Colour-coded switches. / Nature 1993, 362:587-88. CrossRef
16. Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL: Obesity, diabetes, and neoplasia in yellow A
17. Perry WL, Copeland NG, Jenkins NA: The molecular basis for dominant yellow agouti coat color mutations. / Bioessays 1994, 16:705-07. CrossRef
18. Manne J, Argeson AC, Siracusa LD: Mechanisms for the pleiotropic effects of the agouti gene. / Proc Natl Acad Sci USA 1995, 92:4721-724. CrossRef
19. Klebig ML, Wilkinson JE, Woychik RP: Molecular analysis of the mouse
20. Michaud EJ, Mynatt RL, Miltenberger RJ, Klebig ML, Wilkinson JE, Zemel MB, Wilkison WO, Woychik RP: Role of the agouti gene in obesity. / J Endocrinol 1997, 155:207-09. CrossRef
21. Wolff GL, Roberts DW, Mountjoy KG: Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome. / Physiol Genomics 1999, 1:151-63.
22. Wolff GL: Regulation of yellow pigment formation in mice: a historical perspective. / Pigment Cell Res 2003, 16:2-5. CrossRef
23. Michaud EJ, Bultman SJ, Stubbs LJ, Woychik RP: The embryonic lethality of homozygous lethal yellow mice (
24. Michaud EJ, Bultman SJ, Klebig ML, van Vugt MJ, Stubbs LJ, Russell LB, Woychik RP: A molecular model for the genetic and phenotypic characteristics of the mouse lethal yellow (
25. Duhl DMJ, Stevens ME, Vrieling H, Saxon PJ, Miller MW, Epstein CJ, Barsh GS: Pleiotropic effects of the mouse lethal yellow (
26. Duhl DM, Vrieling H, Miller KA, Wolff GL, Barsh GS: Neomorphic agouti mutations in obese yellow mice. / Nat Genet 1994, 8:59-5. CrossRef
27. Kiefer LL, Ittoop OR, Bunce K, Truesdale AT, Willard DH, Nichols JS, Blanchard SG, Mountjoy K, Chen WJ, Wilkison WO: Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors. / Biochemistry 1997, 36:2084-090. CrossRef
28. Kim JH, Kiefer LL, Woychik RP, Wilkison WO, Truesdale A, Ittoop O, Willard D, Nichols J, Zemel MB: Agouti regulation of intracellular calcium: role of melanocortin receptors. / Am J Physiol 1997, 272:E379-84.
29. Yang YK, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS, Gantz I: Effects of recombinant agouti-signaling protein on melanocortin action. / Mol Endocrinol 1997, 11:274-80. me.11.3.274">CrossRef
30. Mountjoy KG, Willard DH, Wilkison WO: Agouti antagonism of melanocortin-4 receptor: greater effect with desacetyl-alpha-melanocyte-stimulating hormone (MSH) than with alpha-MSH. / Endocrinology 1999, 140:2167-172. CrossRef
31. Mountjoy KG, Kong PL, Taylor JA, Willard DH, Wilkison WO: Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells. / Physiol Genomics 2001, 5:11-9.
32. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. / Cell 1997, 88:131-41. CrossRef
33. Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S: A frameshift mutation in MC4R associated with dominantly inherited human obesity. / Nat Genet 1998, 20:111-12. CrossRef
34. Vaisse C, Clement K, Guy-Grand B, Froguel P: A frameshift mutation in human MC4R is associated with a dominant form of obesity. / Nat Genet 1998, 20:113-14. CrossRef
35. Butler AA, Cone RD: The melanocortin receptors: lessons from knockout models. / Neuropeptides 2002, 36:77-4. CrossRef
36. Mynatt RL, Stevens JM: Agouti regulates adipocyte transcription factors. / Am J Physiol Cell Physiol 2001, 280:C954-C961.
37. Jones BH, Kim JH, Zemel MB, Woychik RP, Michaud EJ, Wilkison WO, Moustaid N: Upregulation of adipocyte metabolism by agouti protein: possible paracrine actions in yellow mouse obesity. / Am J Physiol 1996, 270:E192-E196.
38. Heston WE, Vlahakis G: Influence of the
39. Heston WE, Vlahakis G: C3H-
40. Wolff GL: Differential growth of hepatoma-susceptible liver induced by genome × genome interaction. / Cancer Res 1970, 30:1722-725.
41. Wolff GL, Pitot HC: Variation of hepatic malic enzyme capacity with hepatoma susceptibility in mice of different genotypes. / Cancer Res 1972, 32:1861-863.
42. Wolff GL, Morrissey RL, Chen JJ: Amplified response to phenobarbital promotion of hepatotumorigenesis in obese yellow
43. Becker FF: Progression of tumor histiotype during mouse hepatocarcinogenesis associated with the viable yellow (
44. Wolff GL, Roberts DW, Morrissey RL, Greenman DL, Allen RR, Campbell WL, Bergman H, Nesnow S, Frith CH: Tumorigenic responses to lindane in mice: potentiation by a dominant mutation. / Carcinogenesis 1987, 8:1889-897. CrossRef
45. Becker FF: Failure of the viable yellow (
46. Vlahakis G, Heston WE: Increase of induced skin tumors in the mouse by the lethal yellow gene (
47. Hansen LA, Malarkey DE, Wilkinson JE, Rosenberg M, Woychik RP, Tennant RW: Effect of the viable-yellow (
48. Heston WE: Relationship between the lethal yellow (
49. Heston WE, Deringer MK: Relationship between the lethal yellow (
50. Heston WE, Vlahakis G: Elimination of the effect of the
51. Little CC: The relationship of coat color to the spontaneous incidence of mammary tumors in mice. / J Exper Med 1934, 59:229-50. m.59.2.229">CrossRef
52. Vlahakis G, Heston WE, Smith GH: Strain C3H-A-vy-fB mice: ninety percent incidence of mammary tumors transmitted by either parent. / Science 1970, 170:185-87. CrossRef
53. Wolff GL, Medina D, Umholtz RL: Manifestation of hyperplastic alveolar nodules and mammary tumors in "viable yellow" and non-yellow mice. / J Natl Cancer Inst 1979, 63:781-85.
54. Wolff GL, Kodell RL, Cameron AM, Medina D: Accelerated appearance of chemically induced mammary carcinomas in obese yellow (
55. Wolff GL, Gaylor DW, Frith CH, Suber RL: Controlled genetic variation in a subchronic toxicity assay: susceptibility to induction of bladder hyperplasia in mice by 2-acetylaminofluorene. / J Toxicol Environ Health 1983, 12:255-65. CrossRef
56. Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD: An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. / Genes Dev 1987, 1:268-76. CrossRef
57. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP: Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. / Proc Natl Acad Sci USA 1995, 92:4728-732. CrossRef
58. Blanchard SG, Harris CO, Ittoop OR, Nichols JS, Parks DJ, Truesdale AT, Wilkison WO: Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line. / Biochemistry 1995, 34:10406-0411. CrossRef
59. Willard DH, Bodnar W, Harris C, Kiefer L, Nichols JS, Blanchard S, Hoffman C, Moyer M, Burkhart W, Weiel J, Luther MA, Wilkison WO, Rocque WJ: Agouti structure and function: characterization of a potent alpha-melanocyte stimulating hormone receptor antagonist. / Biochemistry 1995, 34:12341-2346. CrossRef
60. Galbraith DB, Wolff GL: Aberrant regulation of the agouti pigment pattern in the viable yellow mouse. / J Hered 1974, 65:137-40.
61. Gantz I, Shimoto Y, Konda Y, Miwa H, Dickinson CJ, Yamada T: Molecular cloning, expression, and characterization of a fifth melanocortin receptor. / Biochem Biophys Res Commun 1994, 200:1214-220. CrossRef
62. Labbe O, Desarnaud F, Eggerickx D, Vassart G, Parmentier M: Molecular cloning of a mouse melanocortin 5 receptor gene widely expressed in peripheral tissues. / Biochemistry 1994, 33:4543-549. CrossRef
63. Fathi Z, Iben LG, Parker EM: Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype. / Neurochem Res 1995, 20:107-13. CrossRef
64. Mountjoy KG, Willard DH, Wilkison WO: Agouti antagonism of melanocortin-4 receptor: greater effect with desacetyl-alpha-melanocyte-stimulating hormone (MSH) than with alpha-MSH. / Endocrinology 1999, 140:2167-172. CrossRef
65. Sambrook J, Fritsch EF, Maniatis T: / Molecular Cloning: A Laboratory Manual / Second Edition Plainview: Cold Spring Harbor Laboratory Press 1989.
66. Overbeek PA, Aguilar-Cordova E, Hanten G, Schaffner DL, Patel P, Lebovitz RM, Lieberman MW: Coinjection strategy for visual identification of transgenic mice. / Transgenic Res 1991, 1:31-7. CrossRef
67. Hogan B, Beddington R, Costantini F, Lacy E: / Manipulating the Mouse Embryo: A Laboratory Manual / Second Edition Plainview: Cold Spring Harbor Laboratory Press 1994.
68. Michaud EJ, van Vugt MJ, Bultman SJ, Sweet HO, Davisson MT, Woychik RP: Differential expression of a new dominant agouti allele ( - 作者单位：Alexander I Kuklin (1) (3)
Randall L Mynatt (1) (4)
Mitchell L Klebig (1) (5)
Laura L Kiefer (2) (6)
William O Wilkison (2) (7)
Richard P Woychik (1) (8)
Edward J Michaud (1)
1. Life Sciences Division, Oak Ridge National Laboratory, P.O. Box 2008, Oak Ridge, TN, 37831, USA
3. Transgenomic, Inc., 12325 Emmet Street, Omaha, NE, 68164, USA
4. Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA
5. Department of Biochemistry and Cellular & Molecular Biology, The University of Tennessee, Knoxville, TN, 37996, USA
2. Glaxo Wellcome, 5 Moore Drive, Research Triangle Park, NC, 27709, USA
6. Paradigm Genetics, 108 Alexander Drive, Research Triangle Park, NC, 27709, USA
7. GlaxoSmithKline, Inc., 5 Moore Drive, Research Triangle Park, NC, 27709, USA
8. The Jackson Laboratory, 600 Main Street, Bar Harbor, ME, 04609, USA - ISSN：1476-4598
文摘
Background The agouti protein is a paracrine factor that is normally present in the skin of many species of mammals. Agouti regulates the switch between black and yellow hair pigmentation by signalling through the melanocortin 1 receptor (Mc1r) on melanocytes. Lethal yellow (A y ) and viable yellow (A vy ) are dominant regulatory mutations in the mouse agouti gene that cause the wild-type protein to be produced at abnormally high levels throughout the body. Mice harboring these mutations exhibit a pleiotropic syndrome characterized by yellow coat color, obesity, hyperglycemia, hyperinsulinemia, and increased susceptibility to hyperplasia and carcinogenesis in numerous tissues, including the liver. The goal of this research was to determine if ectopic expression of the agouti gene in the liver alone is sufficient to recapitulate any aspect of this syndrome. For this purpose, we generated lines of transgenic mice expressing high levels of agouti in the liver under the regulatory control of the albumin promoter. Expression levels of the agouti transgene in the liver were quantified by Northern blot analysis. Functional agouti protein in the liver of transgenic mice was assayed by its ability to inhibit binding of the α-melanocyte stimulating hormone (αMSH) to the Mc1r. Body weight, plasma insulin and blood glucose levels were analyzed in control and transgenic mice. Control and transgenic male mice were given a single intraperitoneal injection (10 mg/kg) of the hepatocellular carcinogen, diethylnitrosamine (DEN), at 15 days of age. Mice were euthanized at 36 or 40 weeks after DEN injection and the number of tumors per liver and total liver weights were recorded. Results The albumin-agouti transgene was expressed at high levels in the livers of mice and produced a functional agouti protein. Albumin-agouti transgenic mice had normal body weights and normal levels of blood glucose and plasma insulin, but responded to chemical initiation of the liver with an increased number of liver tumors compared to non-transgenic control mice. Conclusions The data demonstrate that liver-specific expression of the agouti gene is not sufficient to induce obesity or diabetes, but, in the absence of these factors, agouti continues to promote hepatocellular carcinogenesis.